Joint ASTCT-EBMT Basic and Translational Scientific Retreat

   

The American Society for Transplantation and Cellular Therapy (ASTCT) and EBMT are proud to announce the Inaugural 2021 Joint ASTCT-EBMT Basic and Translational Scientific Retreat, taking place October 13 – 15, 2021.

The Basic and Translational Scientific Retreat will be a 2.5-day conference focused on cutting edge basic and translational biology in the field. The meeting will focus on fundamental themes and novel technologies with an emphasis on unpublished and innovative science. Attendance to the meeting will be limited to 100 attendees with afternoon breaks to allow for informal networking opportunities between junior and senior attendees. The meeting will host two days of poster sessions and a best oral abstract session. 

Health & Safety Registration Agenda Abstracts

DETAILS:

Joint ASTCT – EBMT Basic and Translational Scientific Retreat
October 13 – October 15, 2021
Vail Marriott Mountain Resort
Vail, Colorado, United States

HEALTH & SAFETY:

ASTCT and EBMT are continuing to monitor recommendations from the CDC and WHO. Updates regarding the feasibility of an in-person event will be provided in the coming months. For COVID-19 updates and what to expect at the Vail Marriott Mountain Resort, please visit: https://whattoexpect.marriott.com/whrco

Face coverings will be required in all indoor public areas.

Return to top

TARGET AUDIENCE:

The program is intended for both junior and senior members of the blood and marrow transplantation and cellular therapy field.

REGISTRATION:

Registration to this event is limited to a maximum of 100 total attendees. We are unable to accept additional registrants once the registration capacity has been met.  

Registration will open in mid-May.

Type

Price

Junior Attendee Rate*

$125

Senior Attendee Rate

$250 


*Junior attendees are defined as post doctoral fellows, current fellows, and junior faculty within the first three years of appointment.

The 2021 Joint ASTCT-EBMT Basic and Translational Scientific Retreat will be accepting abstract data/research highlighting the best of basic and translational science. Click here to submit your abstract by Friday, April 30 at 5:00 p.m. CT. Notices regarding abstract submissions will be made available in mid-May.

Lead Investigator(s) for accepted abstracts are required to register for the retreat upon notification of acceptance. Any abstract whose investigator(s) do not register in a timely manner will have their acceptance retracted.

Return to top

*PROGRAM AGENDA:

The program agenda will be broken into three main session topics – Gene editing, GVL, and GVHD. Attendees will have an extended afternoon break to network and explore Vail, Colorado. MT=US Mountain Time Zone.


Day 1: Wednesday, October 13, 2021; Gene Editing

Session Chairs: Harry Dolstra, PhD, Bruce Blazar, MD, and Leslie Kean, MD, PhD

Time

Topic

8:00 – 9:00AM MT

Genome editing for immune deficiencies – efficacy and safety
Toni Cathomen, PhD; University of Freiburg, Freiburg, DE

9:00 – 10:00AM MT

Genome Editing of the Blood: Precise and Potent Cell Based Therapies
Matthew Poretus, MD, PhD; Stanford Medicine, CA, US

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

Session title: TBD
Angelo Lombardo, PhD; IRCCS Ospedale San Raffaele, Milano, IT

11:30 – 12:30PM MT

Expanding the Horizons of Genome Interventions with CRISPR Tools
Anna Cereseto, PhD; University of Trento, Trento, IT

12:30 – 4:30PM MT

Afternoon break – lunch will be available beginning at 12:30PM.

4:30 – 5:30PM MT

Podium Discussion

5:30 – 6:30PM MT

Poster Hall + Networking Hour

6:30 – 7:30PM MT

Dinner + lecture

Speaker: TBD

 

Day 1 concludes

 

Day 2: Thursday, October 14, 2021; Graft-versus-Leukemia

Session Chairs: Chiara Bonini, MD and Warren Shlomchik, MD

Time

Topic

8:00 – 9:00AM MT

Biological Mechanisms and Personalized Therapy of Post-Transplantation Leukemia Relapses
Luca Vago, MD, PhD, San Raffaele Scientific Institute, Milan, IT

9:00 – 10:00AM MT

Mechanisms of GVL Resistance
Warren Shlomchik, MD; University of Pittsburgh, PA, US

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

Immune Escape Mechanisms Causing AML Relapse After Allo-HCT
Robert Zeisser, MD; University of Freiburg, Breisgau, DE

11:30 – 12:30PM MT

Session title: TBD
Philip Greenberg, MD; Fred Hutchinson Cancer Research Center, Seattle, WA, US

12:30 – 4:30PM MT

Afternoon break – lunch will be available beginning at 12:30PM.

4:30 – 5:30PM MT

Meet-the-Professor Session

5:30 – 6:30PM MT

Poster Hall + Networking Hour

6:30 – 7:30PM MT

Dinner + lecture

Speaker: TBD

 

Day 2 concludes

 

 

Day 3: Friday, October 15, 2021; Graft-versus-Host disease

Session Chairs: Pavan Reddy, MD and Nicolaus Kröger, MD

Time

Topic

8:00 – 9:00AM MT

Mechanism of Liver Stem Cell Injury in GVHD - Therapeutic Implications and Interventions
Takanori Teshima, MD, PhD; Hokkaido University, Sapporo, JP

9:00 – 10:00AM MT

Next Challenges in GHVD: From Bedside back to the Bench
Gerard Socié, MD, PhD; Hôpital Saint-Louis, Paris, FR

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

The Microbiome and Graft vs Host Disease
Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, New York City, NY, US

11:30 – 12:30PM MT

Best Abstracts

12:30 – 1:00PM MT

Closing remarks; conference wrap up

 

Day 3 concludes

 

*Please note: session titles and speakers are subject to change. The agenda will be updated as additional information is confirmed.

Return to top

ABSTRACTS:

The 2021 Joint ASTCT-EBMT Basic and Translational Scientific Retreat will be accepting abstract data/research highlighting the best of basic and translational science.

Click here to submit your abstract by Friday, April 30 at 5:00 p.m. CT. Notices regarding abstract submissions will be made available in mid-May.

Abstract Submission Criteria

Abstracts will be scored based on the following criteria:

  • Importance and Relevance: Is a clear rationale for the work provided? Does the study address an important question? Do its findings have the potential to advance the field of blood and marrow or cellular therapies?
  • Originality and Innovation: Is the work novel? Does it present new findings and/or address a problem using an original or improved approach?
  • Quality of Methods and Writing: Are methods well described and valid to answer the question? Is the abstract clear and well written? Is the abstract within the 300-word limit?
    • Please note that the abstract submission form does not have a tracker for word count. We recommend that you prepare your abstract submission in a Word document to confirm that you stay within the 300-word limit. 

The top-scoring abstracts will be selected as Oral Platform Presentations; top-scoring abstracts that are not selected for Oral Platforms will be selected as Distinguished Posters. 

Responsibility of Abstract Authors

The Presenting Author is responsible for the following:

  • Ensuring that all authors have read the abstract and agreed to be co-authors.
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the Joint ASTCT-EBMT Basic and Translational Scientific Retreats.
  • Obtaining all of the conflict-of-interest disclosure information from co-authors.
  • Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
Return to top

Sponsor Opportunities

If you are interested in sponsoring this event, please contact Angie Dahl.